Recent large-scale studies have been successful in identifying common, low-penetrance variants associated with common cancers. One such variant in the caspase-8 (CASP8) gene, D302H (rs1045485), has been confirmed to be associated with breast cancer risk, although the functional effect of this polymorphism (if any) is not yet clear. In order to further map the CASP8 gene with respect to breast cancer susceptibility, we performed extensive haplotype analyses using single nucleotide polymorphisms (SNP) chosen to tag all common variations in the gene (tSNP). We used a staged study design based on 3,200 breast cancer and 3,324 control subjects from the United Kingdom, Utah, and Germany. Using a haplotypemining algorithm in the UK cohort, we identified a four-SNP haplotype that was significantly associated with breast cancer and that was superior to any other single or multi-locus combination (P = 8.0 Â 10 À5
Introduction
Recent genome-wide and candidate gene association studies have started to convincingly identify low-penetrance variants associated with breast cancer (1) (2) (3) (4) . The only confirmed common variant that has emerged from candidate gene studies for breast cancer thus far is in the gene for the apoptosis-related cysteine protease caspase-8 (CASP8), located on chromosome region 2q33 (2, 5, 6) . The rare allele of the nonsynonymous variant D302H (rs1045485) was associated with a reduced risk of breast cancer, with a per allele odds ratio (OR) and 95% confidence interval (95% CI) of 0.88 (0.84-0.92) in a large study of 16,423 cases and 17,109 controls carried out by the Breast Cancer Association Consortium (2) . As yet, there is no known functional effect of rs1045485, and it is nonpolymorphic in Asian populations. Another CASP8 polymorphism, a 6-bp insertion-deletion (indel) in the promoter of CASP8 (rs3834129) was found to reduce breast cancer risk in a Chinese population (7) . However, subsequent larger studies failed to replicate this finding (8, 9) .
The aim of the present work was to use a single nucleotide polymorphism (SNP)-tagging approach to further map the CASP8 gene with respect to breast cancer risk in order to move towards the identification of potential susceptibility variant(s) (10).
Materials and Methods
Case and control subjects. The primary set of case and control subjects were drawn from the Sheffield Breast Cancer Study (SBCS) and consisted of histopathologically confirmed breast cancer patients recruited from the surgical outpatient clinics of the Royal Hallamshire Hospital, Sheffield, United Kingdom between November 1998 and January 2005. Controls were recruited from patients attending the Sheffield Mammography Screening Service between September 2000 and January 2004, whose mammograms showed no evidence of breast lesions. All cases and controls were of North European origin and resident in the Sheffield area (5, 11) . The second set comprised unrelated BRCA1/2 mutation-negative breast cancer patients recruited between 1997 and 2007 by three centers from the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC; refs. 6, 8). All patients had been screened for mutations in the BRCA1 and BRCA2 genes by denaturing high-performance liquid chromatography analysis of all exons followed by direct sequencing. Ethnically matched controls were selected from unrelated healthy female blood donors collected by the Institute of Transfusion Medicine and Immunology (Mannheim, Germany) between the years 2004 and 2007. The Utah Breast Cancer Study (UBCS) cohort consisted of BRCA1/2 mutation-negative cases (established by sequencing, family inference, or linkage evidence) from extended high-risk Utah pedigrees ascertained using the Utah Population Database (12) . Controls were unrelated birth cohort-and sex-matched cancer-free individuals.
Selection of tSNPs. All available HapMap
11 SNPs within a 50 kb region spanning the CASP8 gene, and SNPs from dbSNP 12 with a minor allele frequency of >0.05, were genotyped on 135 random SBCS control samples. The optimal set of 12 tSNPs was identified from these data by principal components analysis (13) . The 12 tSNPs were supplemented by two further SNPs identified by DNA sequencing of regions containing putative SNPs, plus the 6 bp promoter indel variant rs3834129. Thus, a total of 15 SNPs were selected for genotyping.
Genotyping. Genotyping was carried out using the Applied Biosystems SNPlex multiplex system (SBCS samples) or 5 ¶ nuclease PCR (UBCS and GC-HBOC samples). The 6 bp indel was genotyped by fragment analysis on an ABI 3730 automated sequencer. Genotyping quality was assessed by examination of duplicate concordance and call rates for each SNP and a test for compliance with Hardy-Weinberg equilibrium (HWE) in controls. A summary of genotyping quality data is shown in Supplementary Table S1 .
SNPs with duplicate concordance rates of <98%, call rates <90%, or P HWE <0.005 were removed from the analysis.
Statistical analysis. All statistical tests were two-sided. Evidence of association for single SNPs in the primary discovery set was initially assessed by use of a trend test. Per allele and genotypic OR and 95% CIs were estimated within a logistic regression framework with the common homozygotes as reference group. In order to account for familial relatedness in the UBCS subjects, meta-analyses of individual SNPs across study populations were carried out using the Genie software package which uses Monte Carlo testing to derive empirical estimates of significance and CIs (14, 15) .
Pairwise R 2 and D ¶ values were estimated based on genotype data from 123 SBCS controls using Haploview (16) . Haplotype frequencies were estimated by use of the estimation maximization algorithm within SNPHAP. 13 The hapConstructor module of Genie was used to build In the remaining individuals, missing genotypes were internally imputed, and the haplotypes were estimated via the estimation maximization algorithm. The significance thresholds used for the haplotype construction process were 0.05, 0.005, 0.0005, 0.0001 for haplotypes of one to four markers, respectively, and 0.00005 thereafter. Construction-wide false discovery rate (FDR) q values for the best haplotypes, that appropriately account for the construction process, were determined empirically using 100,000 simulations.
Polytomous logistic regression and logistic regression (stratified by study) were used to compare genotype frequencies in different subgroups of cases, based on an additive model for genotype as above. Likelihood ratio testing was used to compare models with and without terms for genotype.
Results
We applied a staged study design based on three case-control population sets; the primary, discovery set (SBCS), and two additional sets to establish the robustness of findings (GC-HBOC and UBCS). A total of 14 SNPs were successfully genotyped in 1,228 case and 1,222 control subjects in the SBCS discovery set (Supplementary Tables S1 and S2 ). Four SNPs (rs3834129, rs6435074, rs6723097, and rs1045485) showed significant associations with breast cancer (P trend < 0.05), with rs6723097 being the most significant, with per allele OR (95% CI) of 1.16 (1.03-1.31; P trend = 0.017; Table 1 ). These four SNPs were genotyped in samples from 1,220 cases and 1,664 controls from GC-HBOC and 752 cases and 438 controls from UBCS (Supplementary Table S2 ). Three of the four SNPs yielded smaller empirical P trend values in the three-study meta-analysis compared with SBCS alone, with rs6723097 again yielding the most significant result (P trend = 0.0008), with no evidence of heterogeneity between studies (Table 1) . Table 2 shows that there is generally a low degree of pairwise correlation between the four SNPs, with the exception of rs6723097 and rs6435074 (R 2 = 0.67). As expected, the D ¶ values are somewhat higher, suggesting that the associated SNPs may be marking one or more underlying breast cancer haplotypes.
With the aim of identifying any such haplotypes that might carry functional etiological variants, we searched for susceptibility haplotypes using the hapConstructor module of Genie in the SBCS data set (17) . Table 3 shows a summary of all haplotypes with a frequency of >1% in SBCS. HapConstructor identified a four-locus haplotype 1-1-2-1 at rs7608692, rs1861269, rs6723097, and rs3817578 as being most significant (P = 8.0 Â 10 À5 ), with a per allele OR (95% CI) of 1.30 (1.12-1.49), and a construction-wide FDR q value of 0.044. This four-allele haplotype has a frequency of 19.8% in controls and 24.2% in cases and is present on haplotypes 2, 8, 11, and 14 ( Table 3 ). The only other four-locus haplotype to surpass the significance thresholds set in the data-mining process was identical at the first three SNP positions and replaced rs3817578 with D302H (rs1045485; P = 1.0 Â 10 À4 ). These two haplotypes constituted 16 of the 18 significant tests that were contained in the group of tests with an FDR of 0.044. Hence, there is extremely good evidence that these related haplotypes are true indicators of an underlying susceptibility variant. Furthermore, in a stepwise logistic regression, the 1-1-2-1 haplotype alone provided the best fitting model, compared with models involving any of the individual SNPs.
To assess the robustness of these results, we also carried out a meta-haplotype construction with the four SNPs typed in the three study populations (rs3834129, rs6435074, rs6723097, and rs1045485). HapConstructor extracted a two-SNP haplotype across rs6723097 and rs1045485 (1, 2) as the most significant (P = 2.0 Â 10 À5 ; FDR q value 0.002), with a protective per allele OR (95% CI) of 0.76 (0.68-0.85). The complement of this haplotype, 2-1, increased risk and was also significant (3.3 Â 10
À4
), with a per allele OR (95% CI) of 1.15 (1.06-1.24). This two-SNP combination also lies on haplotypes 2, 8, 11, and 14 (Table 3) , and these two SNPs are also found on the four-locus risk haplotype in the discovery analysis. Thus, the meta-analysis haplotypic associations are extremely consistent with the four-allele haplotype association seen in SBCS.
A case-only meta-analysis across the three studies yielded no evidence that either the individual SNPs or the haplotypes were associated with age at onset, family history, bilateral disease, or estrogen or progesterone receptor tumor status (data not shown).
Discussion
Our haplotype-mining results, based on three independent data sets, provide evidence that an extended multilocus CASP8 haplotype is associated with breast cancer. The risk haplotype provides a better fitting model than any combination of the individual SNPs. This suggests that additional untyped variants carried on this haplotype may be responsible for the increased breast cancer risk. Resequencing of DNA samples from individuals carrying the highrisk and low-risk haplotypes should allow the underlying causative variants to be identified. Such variants might affect the molecular interactions of caspase-8, caspase-8 activity (coding variants), or caspase-8 levels via effects on transcription factor binding, RNA splicing, or RNA stability (intronic/intergenic variants).
Aside from a well-defined role as an initiator of apoptosis, caspase-8 has been proposed as a molecular switch between cell motility (promoted by procaspase-8) and apoptosis (promoted by mature caspase-8) (18) . Caspase-8 processing to the mature form is in turn controlled by phosphorylation by c-SRC, a proto-oncogene tyrosine kinase whose activity is up-regulated in many types of tumor (19) . It will be important to determine whether cancerassociated variants in CASP8 affect these processes. Furthermore, it is intriguing to note that although the rare allele of CASP8 D302H is associated with a decreased risk of breast cancer, it is associated with an increased risk of glioma (20) . Further studies including more comprehensive SNP panels and cancer characteristics are therefore needed to help us understand the roles of caspase-8 in different cancer types.
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